(NASDAQ: ALT) Altimmune's forecast annual revenue growth rate of 2,271.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Altimmune's revenue in 2025 is $15,000.On average, 1 Wall Street analysts forecast ALT's revenue for 2026 to be $17,651,450,600, with the lowest ALT revenue forecast at $17,651,450,600, and the highest ALT revenue forecast at $17,651,450,600. On average, 2 Wall Street analysts forecast ALT's revenue for 2027 to be $7,309,906,980, with the lowest ALT revenue forecast at $3,265,518,361, and the highest ALT revenue forecast at $11,354,295,598.
In 2028, ALT is forecast to generate $52,864,329,402 in revenue, with the lowest revenue forecast at $1,809,273,687 and the highest revenue forecast at $144,463,002,001.